Targeting p38 MAPK to treat Friedreich ataxia

p38 MAPK activation as a therapeutic target for Friedreich ataxia

['FUNDING_R01'] · CHILDREN'S HOSP OF PHILADELPHIA · NIH-11049076

This study is looking at how a specific pathway in the body might be making Friedreich ataxia worse, and it hopes to find new treatments that could help improve symptoms and slow down the disease for those living with it.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorCHILDREN'S HOSP OF PHILADELPHIA (nih funded)
Locations1 site (PHILADELPHIA, UNITED STATES)
Trial IDNIH-11049076 on ClinicalTrials.gov

What this research studies

This research investigates the role of the p38 MAP kinase pathway in Friedreich ataxia, a genetic disorder that affects the nervous and cardiovascular systems. The study aims to understand how the hyperactivation of this pathway contributes to the disease and explores potential therapies that could inhibit this activation. By targeting the p38 pathway, the researchers hope to improve the biogenesis of iron-sulfur clusters, which are crucial for cellular function. Patients may benefit from new treatment strategies that could alleviate symptoms and slow disease progression.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Friedreich ataxia, particularly those experiencing neurological and cardiac symptoms.

Not a fit: Patients with other forms of ataxia or those without a diagnosis of Friedreich ataxia may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to effective therapies for Friedreich ataxia, improving quality of life for patients.

How similar studies have performed: While targeting the p38 MAPK pathway is a novel approach in Friedreich ataxia, similar strategies have shown promise in other neurodegenerative conditions.

Where this research is happening

PHILADELPHIA, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.